Drugs.com - Clinical Trials

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema...

Feb 9, 2025 - 21:44
 0
CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial
Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema...
Read More

Tags:

Previous Article

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clini...

Next Article

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staph...

Related Posts

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics Announces Successful Completion and...

Feb 9, 2025  0

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus

LimmaTech Awarded FDA Fast Track Designation for Vaccin...

Feb 9, 2025  0

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

Vertex Announces Results From Phase 2 Study of Suzetrig...

Feb 9, 2025  0